Journal Article

Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study

  • Schuetze S
  • Rothe M
  • Mangat P
  • et al.
JCO Precision Oncology (2024) (8)
DOI: 10.1200/po.24.00219
11Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Palbociclib met @ASCO #TAPUR criteria to declare antitumor activity in patients with CDK4-amplified liposarcoma.

Cite

CITATION STYLE

APA

Schuetze, S., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Meric-Bernstam, F., Calfa, C. J., … Schilsky, R. L. (2024). Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, (8). https://doi.org/10.1200/po.24.00219

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free